Date: 2015-11-05
Type of information: Licensing agreement
Compound: cell line development technology
Company: Agenus (USA - MA) Selexis (Switzerland)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism:
Disease:
Details: * On November 5, 2015, Agenus announced that it has entered into an agreement for cell line development technology with Selexis. These new capabilities, in combination with Agenus’s Retrocyte Display™ and SECANT® yeast display platforms, will result in a broad, vertically integrated and highly productive in-vitro antibody discovery and production platform. The Selexis collaboration will offer Agenus significant advantages in the creation of high expressing and stable master cell lines needed for antibody manufacturing.
Financial terms:
Latest news:
